The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee
entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups. This study is for people ages 6 and older.
Age:
6 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
No FEV1 Limit
Number of Visits:
3
Length of Participation:
48 days
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.